For the quarter ending 2026-03-31, SHC had -$30,511K decrease in cash & cash equivalents over the period. -$16,731K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | 26,589 | 34,847 | 48,400 | -5,298 |
| Depreciation | 25,212 | 26,974 | 22,711 | 23,093 |
| Amortization of intangible assets | 5,602 | 5,552 | 5,649 | 11,923 |
| Loss on refinancing of debt | - | -295 | -1,087 | -80 |
| Deferred income taxes | 4,167 | 16,935 | 8,186 | -9,024 |
| Share-based compensation expense | 14,393 | 7,568 | 7,949 | 8,119 |
| Accretion of asset retirement obligations | 673 | 584 | 601 | 562 |
| Unrealized foreign exchange (gain) loss | 2,102 | -1,139 | 10,508 | -13,527 |
| Unrealized loss on derivatives not designated as hedging instruments | -1,194 | 258 | -1,389 | 3,598 |
| Amortization of debt issuance costs | 1,467 | 1,484 | 1,305 | 1,375 |
| Other | 1,656 | 526 | 1,275 | 1,006 |
| Accounts receivable | -891 | -4,495 | 6,428 | 4,546 |
| Inventories | 4,088 | 3,754 | -9,040 | -4,176 |
| Other current assets | 2,997 | -6,046 | 4,698 | 10,557 |
| Accounts payable | 2,815 | 7,987 | -8,375 | -6,098 |
| Accrued liabilities | -10,862 | -11,338 | 27,793 | -4,345 |
| Litigation settlement-Ethylene Oxide Tort Litigation Illinois | - | - | - | -34,000 |
| Illinois eo litigation settlements | -34,000 | 0 | 34,000 | - |
| Litigation settlement-Ethylene Oxide Tort Litigation Georgia | - | 0 | 0 | 0 |
| Income taxes payable / receivable, net | 4,049 | 4,083 | -1,332 | -7,656 |
| Other liabilities | -200 | 439 | -117 | -98 |
| Other long-term assets | 1,712 | -552 | -720 | 473 |
| Net cash provided by operating activities | 29,435 | 103,104 | 71,154 | 57,416 |
| Purchases of property, plant and equipment | 46,166 | 50,699 | 36,172 | 31,229 |
| Other investing activities | -1,038 | 0 | -2,837 | 0 |
| Net cash used in investing activities | -45,128 | -50,699 | -33,335 | -31,229 |
| Proceeds from long-term borrowings | - | 0 | 0 | 0 |
| Payment of revolving credit facility | - | 0 | - | - |
| Payments of debt issuance costs and debt discount | - | 455 | 1,593 | 2,326 |
| Payment on long-term borrowings | 3,558 | 3,557 | 75,000 | 3,774 |
| Buyout of leased facility | - | 0 | 0 | 0 |
| Payments of debt issuance costs | 0 | - | - | - |
| Shares withheld for employee taxes on equity awards | 8,802 | 2,707 | 207 | 54 |
| Other financing activities | -419 | -1,456 | -539 | -789 |
| Net cash used in financing activities | -12,779 | -8,175 | -77,339 | -6,933 |
| Effect of exchange rate changes on cash and cash equivalents | -2,039 | 1,200 | 6,274 | 8,937 |
| Net (decrease) increase in cash and cash equivalents, including restricted cash | -30,511 | 45,430 | -33,246 | 28,191 |
| Cash and cash equivalents, including restricted cash, at beginning of period | 346,456 | 301,026 | 334,272 | 306,081 |
| Cash and cash equivalents, including restricted cash, at end of period | 315,945 | 346,456 | 301,026 | 334,272 |
Sotera Health Co (SHC)
Sotera Health Co (SHC)